Mg doped Li2FeSiO4/C nanocomposites synthesized by the solvothermal method for lithium ion batteries.

A series of porous Li2Fe1-xMgxSiO4/C (x = 0, 0.01, 0.02, 0.04) nanocomposites (LFS/C, 1Mg-LFS/C, 2Mg-LFS and 4Mg-LFS/C) have been synthesized via a solvo-thermal method using the Pluronic P123 polymer as an in situ carbon source. Rietveld refinement of the X-ray diffraction data of Li2Fe1-xMgxSiO4/C composites confirms the formation of the monoclinic P21 structure of Li2FeSiO4. The addition of Mg facilitates the growth of impurity-free Li2FeSiO4 with increased crystallinity and particle size. Despite having the same percentage of carbon content (∼15 wt%) in all the samples, the 1Mg-LFS/C nanocomposite delivered the highest initial discharge capacity of 278 mA h g-1 (∼84% of the theoretical capacity) at the C/30 rate and also exhibited the best rate capability and cycle stability (94% retention after 100 charge-discharge cycles at 1C). This is attributed to its large surface area with a narrow pore size distribution and a lower charge transfer resistance with enhanced Li-ion diffusion coefficient compared to other nanocomposites.

Fabrication of flexible and self-standing inorganic-organic three phase magneto-dielectric PVDF based multiferroic nanocomposite films through a small loading of graphene oxide (GO) and Fe3O4 nanoparticles.

Flexible inorganic-organic magneto-electric (ME) nanocomposite films (PVDF, PVDF-GO, PVDF-Fe3O4 and PVDF-GO-Fe3O4), composed of well-dispersed graphene oxide (GO 5 wt%) and magnetic Fe3O4 nanoparticles (5 wt%) embedded into a poly(vinylidene-fluoride) (PVDF) matrix, have been prepared by a solvent casting route. The magnetic, ferroelectric, dielectric, magneto-dielectric (MD) coupling and structural properties of these films have been systematically investigated. Magnetic (Ms = 2.21 emu g(-1)) and ferroelectric (P = 0.065 µC cm(-2)) composite films of PVDF-GO-Fe3O4 (PVDF loaded with 5% GO and 5% Fe3O4) with an MD coupling of 0.02% at room temperature (RT) showed a three times higher dielectric constant than that of the pure PVDF film, with a dielectric loss as low as 0.6. However, the PVDF-Fe3O4 film, which exhibited improved magnetic (Ms = 2.5 emu g(-1)) and MD coupling (0.04%) properties at RT with a lower dielectric loss (0.3), exhibited decreased ferroelectric properties (P = 0.06 µC cm(-2)) and dielectric constant compared to the PVDF-GO-Fe3O4 film. MD coupling measurements carried out as a function of temperature on the multi-functional PVDF-GO-Fe3O4 film showed a systematic increase in MD values up to 100 K and a decrease thereafter. The observed magnetic, ferroelectric, dielectric, MD coupling and structural properties of the nanocomposite films are attributed to the homogeneous dispersion and good alignment of Fe3O4 nanoparticles and GO in the PVDF matrix along with a partial conversion of nonpolar α-phase PVDF to polar ß-phase. The above multi-functionality of the composite films of PVDF-Fe3O4 and PVDF-GO-Fe3O4 paves the way for their application in smart multiferroic devices.

Vision 20/20: the role of Raman spectroscopy in early stage cancer detection and feasibility for application in radiation therapy response assessment.

Raman spectroscopy is an optical technique capable of identifying chemical constituents of a sample by their unique set of molecular vibrations. Research on the applicability of Raman spectroscopy in the differentiation of cancerous versus normal tissues has been ongoing for many years, and has yielded successful results in the context of prostate, breast, brain, skin, and head and neck cancers as well as pediatric tumors. Recently, much effort has been invested on developing noninvasive "Raman" probes to provide real-time diagnosis of potentially cancerous tumors. In this regard, it is feasible that the Raman technique might one day be used to provide rapid, minimally invasive real-time diagnosis of tumors in patients. Raman spectroscopy is relatively new to the field of radiation therapy. Recent work involving cell lines has shown that the Raman technique is able to identify proteins and other markers affected by radiation therapy. Although this work is preliminary, one could ask whether or not the Raman technique might be used to identify molecular markers that predict radiation response. This paper provides a brief review of Raman spectroscopic investigations in cancer detection, benefits and limitations of this method, advances in instrument development, and also preliminary studies related to the application of this technology in radiation therapy response assessment.

Raman spectroscopy can differentiate malignant tumors from normal breast tissue and detect early neoplastic changes in a mouse model.

Raman spectroscopy shows potential in differentiating tumors from normal tissue. We used Raman spectroscopy with near-infrared light excitation to study normal breast tissue and tumors from 11 mice injected with a cancer cell line. Spectra were collected from 17 tumors, 18 samples of adjacent breast tissue and lymph nodes, and 17 tissue samples from the contralateral breast and its adjacent lymph nodes. Discriminant function analysis was used for classification with principal component analysis scores as input data. Tissues were examined by light microscopy following formalin fixation and hematoxylin and eosin staining. Discriminant function analysis and histology agreed on the diagnosis of all contralateral normal, tumor, and mastitis samples, except one tumor which was found to be more similar to normal tissue. Normal tissue adjacent to each tumor was examined as a separate data group called tumor bed. Scattered morphologically suspicious atypical cells not definite for tumor were present in the tumor bed samples. Classification of tumor bed tissue showed that some tumor bed tissues are diagnostically different from normal, tumor, and mastitis tissue. This may reflect malignant molecular alterations prior to morphologic changes, as expected in preneoplastic processes. Raman spectroscopy not only distinguishes tumor from normal breast tissue, but also detects early neoplastic changes prior to definite morphologic alteration.

Raman spectroscopy for neoplastic tissue differentiation: a pilot study.

BACKGROUND: Several changes occur during the transformation of normal tissue to neoplastic tissue. Such changes in molecular composition can be detected by Raman spectroscopy. Raman spectroscopy is a nondestructive method of measuring these changes, which suggests the possibility of real-time diagnosis during medical procedures. METHODS: This study seeks to evaluate the ability of Raman spectra to distinguish tissues. The Raman signatures of normal kidney, lung, and liver tissue samples from pigs and rats were characterized in vitro. Further, a human neuroblastoma and a hepatoblastoma, obtained at resection were also studied. RESULTS: The Raman spectra of the animal samples of kidney, liver, and lung are distinctly different in the intensity distribution of the Raman peaks. Further, the spectra of a given organ from pigs and rats, although similar, were different enough to distinguish between the 2 animals. In the patient tissues, the Raman spectra of normal liver, viable tumor, and fibrotic hepatoblastoma were very different. Fibrotic tissue showed a greater concentration of carotenoids, whereas viable tissue was rich in proteins and nucleic acids. The normal tissue showed both components. Similar differences were also seen in the neuroblastoma tissue. CONCLUSIONS: The results of this study show the potential use of Raman spectroscopy in clinical diagnosis.